Commentary

Video

Unveiling the Latest in HER2+ Breast Cancer and Beyond With Drs Sara Hurvitz and Neil Iyengar

Author(s):

Chandler Park, MD, MSc, FACP,Sara A. Hurvitz, MD, FACP

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Related Videos
Laura A. Huppert, MD
Polly Niravath, MD
Charles E. Geyer, Jr., MD
Alexis LeVee, MD
Junjie Li, MD
2 experts are featured in this series.
Sagar D. Sardesai, MBBS
DB-12
Related Content
Cancer | Image Credit: © Katsyarina – stock.adobe.com
January 9th 2025

Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Melanoma | Maris– stock.adobe.com
January 4th 2025

BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy

James J. Harding, MD, director, Early Drug Development, Memorial Sloan Kettering Cancer Center
December 30th 2024

FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer

Kelly K. Hunt, MD, FACS, FSSO, of MD Anderson Cancer Center
January 3rd 2025

One Surgeon’s Spirit and Brilliance Lift a Whole Community

Alison Schram, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center
January 2nd 2025

FDA Approval Insights: Zenocutuzumab for NRG1+ Pancreatic Adenocarcinoma and NSCLC: With Alison Schram, MD